Armata Pharmaceuticals, Inc. filed its 10-K on Mar 16, 2023 for the period ending Dec 31, 2022. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.51 USD | +0.80% | -3.46% | -22.53% |
Mar. 21 | Earnings Flash (ARMP) ARMATA PHARMACEUTICALS Reports Q4 Revenue $1.5M | MT |
Mar. 21 | Armata Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.53% | 90.02M | |
+22.81% | 47.9B | |
+46.56% | 41.42B | |
-1.88% | 40.7B | |
-6.20% | 28.92B | |
+11.33% | 25.55B | |
-21.00% | 19.27B | |
-1.43% | 12.15B | |
+30.73% | 12.14B | |
-0.48% | 11.99B |
- Stock Market
- Equities
- ARMP Stock
- News Armata Pharmaceuticals, Inc.
- Armata Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt